Design Therapeutics (DSGN) Amortizatization of Intangibles (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Amortizatization of Intangibles of $15000.0 for Q2 2026, down 98.36% year-over-year from $914000.0 in Q2 2025, and down 89.8% on a QoQ basis from $147000.0 in Q1 2026.
Powered by 
Analysis
Design Therapeutics (DSGN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Amortizatization of Intangibles for 7 years, with the latest figure at $15000.0 in Q2 2026.
- Amortizatization of Intangibles for Q2 2026 came in at $15000.0, down 98.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 million (down 70.4% YoY), and the FY2025 annual result was $3.3 million, down 47.52% from the prior year.
- Amortizatization of Intangibles fell to $15000.0 in Q2 2026, from $147000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.8 million in Q4 2023 and troughed at -$19000.0 in Q1 2022.
- A 5-year average of $949611.1 and a median of $987000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The widest annual swing landed in 2022, when Amortizatization of Intangibles slumped 112.67%; it then soared 6110.53% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $899000.0 in 2022, then soared by 104.23% to $1.8 million in 2023, then retreated by 21.68% to $1.4 million in 2024, then slumped by 64.39% to $512000.0 in 2025, then slumped by 97.07% to $15000.0 in 2026.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were $15000.0 in Q2 2026, $147000.0 in Q1 2026, and $512000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | 15,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.84 Mn |
| Sep 30, 2023 | 1.71 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 899,000.00 |
| Sep 30, 2022 | 458,000.00 |
| Jun 30, 2022 | 58,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Sep 30, 2021 | -25,000.00 |